A RETROSPECTIVE ANALYSIS OF SPONTANEOUSLY REPORTED ADVERSE DRUG REACTIONS TO ANTIRETROVIRAL THERAPY DURING AND POST-TRANSITIONAL PHASE OF DOLUTEGRAVIR
DOI:
https://doi.org/10.22159/ajpcr.2023.v16i10.48106Keywords:
Dolutegravir, Antiretroviral Regimen, Peripheral Neuropathy, Hyperglycaemia, Adverse Drug ReactionsAbstract
Objectives: The main objective of this study was to analyze the pattern of reported adverse drug reaction (ADRs) in people receiving antiretroviral therapy (ART) mainly during and post-transitional phase of dolutegravir-based regimens.
Methods: This is a retrospective observational study initiated after the approval of the Institutional Ethics Committee and from the ART Center. Sources of data are spontaneously reported ADR data of human immunodeficiency virus (HIV) persons to the ADR monitoring center (AMC).
Results: A total of 190 patients who are on ART reported at AMC from April 2020 to June 2022 had a total of 204 ADRs. Among them, 108 (57%) were females and had a higher prevalence than 82 (43%) males. ADRs were higher among the age group of 41–50 years (33.68%) followed by 31–40 years (32.10%). Among dolutegravir-based regimens, tenofovir, lamivudine, and dolutegravir were given to more patients (118). The most common ADRs encountered were peripheral neuropathy 16.66%, followed by hyperglycemia (14.21%), renal toxicity (10.29%), hyperbilirubinemia (9.31%), and anemia (7.84%) of all ADRs.
Conclusion: In this study, it has been observed that HIV patients on dolutegravir-based regimens are associated with more ADRs. Nervous system disorders were the most commonly observed group of ADRs, followed by metabolism and nutritional disorders, the others being skin diseases and renal toxicity. This incidence of ADRs to ART calls for efficient pharmacovigilance surveillance to improve patient care and drug safety.
Downloads
References
World Health Organization. HIV/AIDS. Available from: https://www. who.int/health-topics/hiv-aids#
Anwikar SR, Bandekar MS, Smrati B, Pazare AP, Tatke PA, Kshirsagar NA. HAART induced adverse drug reactions: A retrospective analysis at a tertiary referral health care center in India. Int J Risk Saf Med 2011;23:163-9. doi: 10.3233/JRS-2011-0532, PMID 22020396
Wadesango L, Wiafe E, Padayachee N, Mensah K, Bangalee V. Dolutegravir reported adverse drug reactions: A systematic review protocol. Syst Rev Pharm 2022;13:635-8.
Rukmangathen R, Brahmanapalli VD, Thammisetty DP, Pemmasani D, Gali SD, Atmakuru RB. Study of adverse drug reactions to antiretroviral therapy in a tertiary care hospital, Tirupati. Perspect Clin Res 2020;11:158-63. doi: 10.4103/picr.PICR_133_18, PMID 33489833
Chowta MN, Kamath P, Ramapuram JT, Shenoy KA, Hadigal S. Evaluation of adverse drug reaction profile of drugs used as first-line antiretroviral therapy. Interdiscip Perspect Infect Dis 2018;2018:8095609. doi: 10.1155/2018/8095609, PMID 30174689
Guidance Document for Spontaneous Adverse Drug Reaction Reporting. Indian Pharmacopoeia Commission. Available from: https:// who-umc.org/media/1075/india.pdf [Last accessed on 2022 Oct 11].
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49:2229-32. doi: 10.1093/ajhp/49.9.2229, PMID 1524068
Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992;27:538. PMID 10118597
Patil PT, Pawar MP, Halasawadekar NR, Shinde MP, Kumbhar AV, Rathod MS. Current pattern of adverse drug reactions to anti-retroviral therapy in an antiretroviral therapy centre attached to a government medical college of Maharashtra, India: A retrospective study. Int J Basic Clin Pharmacol 2016;5:2438-43. doi: 10.18203/2319-2003. ijbcp20164101
Reddy AV, Lihite RJ, Lahkar M, Choudhury U, Baruah SK. A study on adverse drug reactions in HIV infected patients at a art centre of tertiary care hospital in Guwahati, India. Asian J Pharm Clin Res 2013;6:102-4.
Vilholm OJ, Christensen AA, Zedan AH, Itani M. Drug-induced peripheral neuropathy. Basic Clin Pharmacol Toxicol 2014;115:185-92. doi: 10.1111/bcpt.12261, PMID 24786912
Namulindwa A, Wasswa JH, Muyindike W, Tamukong R, Oloro J. Prevalence and factors associated with adverse drug events among patients on dolutegravir-based regimen at the Immune Suppression Syndrome Clinic of Mbarara Regional Referral Hospital, Uganda: A mixed design study. AIDS Res Ther 2022;19:18. doi: 10.1186/ s12981-022-00442-7, PMID 35366917
McLaughlin M, Walsh S, Galvin S. Dolutegravir-induced hyperglycaemia in a patient living with HIV. J Antimicrob Chemother 2018;73:258-60. doi: 10.1093/jac/dkx365, PMID 29077869
Panagopoulos P, Maltezos E, Hatzakis A, Paraskevis D. Hyperbilirubinemia in atazanavir treated HIV-infected patients: The impact of the UGT1A1*28 allele. Pharmgenomics Pers Med 2017;10:205-8. doi: 10.2147/PGPM.S107152, PMID 28790862
Kumar A, Majhee L, Gari M. Causality, severity and preventability assessment of adverse drug reactions in patients received anti-retroviral therapy in a tertiary care hospital: A retrospective study. Natl J Physiol Pharm Pharmacol 2017;7:178. doi: 10.5455/ njppp.2017.7.0821922082016
Published
How to Cite
Issue
Section
Copyright (c) 2023 PILLA S SURYA DURGA DEVI, KATIKITALLA SWAROOPA, S. KEERTHANA, R. SRINIVASA RAO
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
